Somewhat Favorable Media Coverage Somewhat Unlikely to Affect PDL BioPharma (PDLI) Stock Price

Media stories about PDL BioPharma (NASDAQ:PDLI) have trended somewhat positive on Monday, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. PDL BioPharma earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.0909576061468 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news headlines that may have effected Accern Sentiment’s scoring:

Shares of PDL BioPharma (PDLI) traded down 2.95% on Monday, hitting $2.96. The company had a trading volume of 2,961,818 shares. PDL BioPharma has a 12-month low of $1.93 and a 12-month high of $3.77. The firm has a 50 day moving average of $3.34 and a 200-day moving average of $2.69. The firm has a market capitalization of $456.08 million, a P/E ratio of 6.80 and a beta of 0.49.

PDL BioPharma (NASDAQ:PDLI) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.09 by $0.17. PDL BioPharma had a return on equity of 9.07% and a net margin of 23.03%. The firm had revenue of $143.80 million during the quarter, compared to analysts’ expectations of $56.30 million. During the same period in the prior year, the firm posted $0.09 earnings per share. The business’s quarterly revenue was up 584.8% compared to the same quarter last year. On average, equities analysts predict that PDL BioPharma will post $0.61 EPS for the current year.

PDL BioPharma announced that its board has initiated a stock repurchase plan on Monday, September 25th that allows the company to repurchase $25.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to reacquire shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

A number of equities research analysts have recently weighed in on the company. BidaskClub raised PDL BioPharma from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Cowen and Company reaffirmed a “hold” rating and set a $3.00 price target on shares of PDL BioPharma in a research note on Friday. Piper Jaffray Companies reaffirmed a “buy” rating and set a $4.00 price target on shares of PDL BioPharma in a research note on Thursday, August 10th. ValuEngine raised PDL BioPharma from a “hold” rating to a “buy” rating in a research note on Friday, August 4th. Finally, Zacks Investment Research raised PDL BioPharma from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research note on Wednesday, August 16th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $3.33.

ILLEGAL ACTIVITY WARNING: This article was reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.com-unik.info/2017/10/30/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-pdl-biopharma-pdli-stock-price.html.

About PDL BioPharma

PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.

Insider Buying and Selling by Quarter for PDL BioPharma (NASDAQ:PDLI)

What are top analysts saying about PDL BioPharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PDL BioPharma Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit